Capital World Investors Alnylam Pharmaceuticals, Inc. Transaction History
Capital World Investors
- $592 Billion
- Q1 2025
A detailed history of Capital World Investors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital World Investors holds 16,749,623 shares of ALNY stock, worth $5.37 Billion. This represents 0.76% of its overall portfolio holdings.
Number of Shares
16,749,623
Previous 16,600,525
0.9%
Holding current value
$5.37 Billion
Previous $3.91 Billion
15.78%
% of portfolio
0.76%
Previous 0.62%
Shares
16 transactions
Others Institutions Holding ALNY
# of Institutions
722Shares Held
111MCall Options Held
978KPut Options Held
881K-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.19 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.06 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.3 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.42 Billion0.79% of portfolio
-
Baillie Gifford & CO3.66MShares$1.17 Billion0.89% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $39.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...